TDACW
TDACW
Translational Development Acquisition Corp.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K ▲ | $-8.04K ▲ | 0% | $-0 ▲ | $-135.07K ▼ |
| Q3-2024 | $0 | $61.28K | $-61.28K | 0% | $-0.02 | $-61.28K |
What's going well?
The company posted a profit and slightly higher EPS, thanks to large non-operating income. No share dilution and no interest or tax burden this quarter.
What's concerning?
Revenue dropped sharply, costs are out of control, and the core business is losing money. Profits rely on one-off items, not sustainable operations.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K ▲ | $175M ▲ | $6.25M ▲ | $168.75M ▲ |
| Q3-2024 | $224.04K | $393.77K | $964.4K | $-570.63K |
What's financially strong about this company?
The company has almost no debt, a large base of investments, and high shareholder equity. Debt was paid down aggressively this quarter.
What are the financial risks or weaknesses?
Cash is extremely low and current liabilities far exceed current assets, so the company could struggle to pay bills in the short term. Most assets are not liquid, and there are negative retained earnings.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K ▲ | $-810.96K ▼ | $-174.22M ▼ | $175.25M ▲ | $214.14K ▲ | $-810.96K ▼ |
| Q3-2024 | $-61.28K | $-40.48K | $0 | $192.5K | $152.02K | $-40.48K |
What's strong about this company's cash flow?
The company is still able to raise outside funding and is returning cash to shareholders through dividends. Working capital provided a small cash boost this quarter.
What are the cash flow concerns?
Core operations are burning over $1.2M in cash each quarter, and the company is paying out more in dividends than it generates. Cash on hand is very low, and the business is highly dependent on outside funding to survive.
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDACW’s main strengths are financial and structural rather than operational. It now holds a large pool of cash and liquid investments, has eliminated debt, and shows a strong short-term liquidity position. These features give it flexibility to pursue a business combination and reduce the risk of financial distress while it searches. The SPAC structure also offers a ready-made route for a private company to access public markets, which can be attractive to potential targets if terms are compelling.
The key risks center on the absence of an operating business and the reliance on executing a single transformative transaction. The company has no revenue, persistent accounting losses, and consistently negative operating and free cash flow, so it must depend on existing capital and any further financing it can raise. There is also deal risk (failing to find a suitable target), valuation risk (overpaying for a target), redemption and dilution risk for existing holders, and timing risk given the finite life typical of SPAC structures.
The outlook for TDACW is binary and highly contingent. If it successfully merges with a strong, fundamentally sound operating company, its financial profile, risks, and opportunities will be completely reshaped and must be reassessed from the ground up. If it does not complete a suitable merger within required timeframes, the likely path is returning capital to shareholders, with limited value creation beyond preserving trust funds. Until a concrete target is announced and detailed, the financials mainly describe a well-capitalized shell whose future depends on the sponsors’ ability to execute a disciplined, value-aware transaction in a competitive and evolving SPAC landscape.
About Translational Development Acquisition Corp.
https://www.translational-development.co...Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K ▲ | $-8.04K ▲ | 0% | $-0 ▲ | $-135.07K ▼ |
| Q3-2024 | $0 | $61.28K | $-61.28K | 0% | $-0.02 | $-61.28K |
What's going well?
The company posted a profit and slightly higher EPS, thanks to large non-operating income. No share dilution and no interest or tax burden this quarter.
What's concerning?
Revenue dropped sharply, costs are out of control, and the core business is losing money. Profits rely on one-off items, not sustainable operations.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K ▲ | $175M ▲ | $6.25M ▲ | $168.75M ▲ |
| Q3-2024 | $224.04K | $393.77K | $964.4K | $-570.63K |
What's financially strong about this company?
The company has almost no debt, a large base of investments, and high shareholder equity. Debt was paid down aggressively this quarter.
What are the financial risks or weaknesses?
Cash is extremely low and current liabilities far exceed current assets, so the company could struggle to pay bills in the short term. Most assets are not liquid, and there are negative retained earnings.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K ▲ | $-810.96K ▼ | $-174.22M ▼ | $175.25M ▲ | $214.14K ▲ | $-810.96K ▼ |
| Q3-2024 | $-61.28K | $-40.48K | $0 | $192.5K | $152.02K | $-40.48K |
What's strong about this company's cash flow?
The company is still able to raise outside funding and is returning cash to shareholders through dividends. Working capital provided a small cash boost this quarter.
What are the cash flow concerns?
Core operations are burning over $1.2M in cash each quarter, and the company is paying out more in dividends than it generates. Cash on hand is very low, and the business is highly dependent on outside funding to survive.
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDACW’s main strengths are financial and structural rather than operational. It now holds a large pool of cash and liquid investments, has eliminated debt, and shows a strong short-term liquidity position. These features give it flexibility to pursue a business combination and reduce the risk of financial distress while it searches. The SPAC structure also offers a ready-made route for a private company to access public markets, which can be attractive to potential targets if terms are compelling.
The key risks center on the absence of an operating business and the reliance on executing a single transformative transaction. The company has no revenue, persistent accounting losses, and consistently negative operating and free cash flow, so it must depend on existing capital and any further financing it can raise. There is also deal risk (failing to find a suitable target), valuation risk (overpaying for a target), redemption and dilution risk for existing holders, and timing risk given the finite life typical of SPAC structures.
The outlook for TDACW is binary and highly contingent. If it successfully merges with a strong, fundamentally sound operating company, its financial profile, risks, and opportunities will be completely reshaped and must be reassessed from the ground up. If it does not complete a suitable merger within required timeframes, the likely path is returning capital to shareholders, with limited value creation beyond preserving trust funds. Until a concrete target is announced and detailed, the financials mainly describe a well-capitalized shell whose future depends on the sponsors’ ability to execute a disciplined, value-aware transaction in a competitive and evolving SPAC landscape.

CEO
Michael Hoffman
Compensation Summary
(Year )
Ratings Snapshot
Rating : B

